Elevation Oncology Net Worth
Elevation Oncology Net Worth Breakdown | ELEV |
Elevation Oncology Net Worth Analysis
Elevation Oncology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Elevation Oncology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Elevation Oncology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Elevation Oncology's net worth analysis. One common approach is to calculate Elevation Oncology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Elevation Oncology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Elevation Oncology's net worth. This approach calculates the present value of Elevation Oncology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Elevation Oncology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Elevation Oncology's net worth. This involves comparing Elevation Oncology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Elevation Oncology's net worth relative to its peers.
Enterprise Value |
|
To determine if Elevation Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Elevation Oncology's net worth research are outlined below:
| Elevation Oncology generated a negative expected return over the last 90 days | |
| Elevation Oncology has some characteristics of a very speculative penny stock | |
| Elevation Oncology has high historical volatility and very poor performance | |
| Elevation Oncology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (45.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Elevation Oncology currently holds about 122.54 M in cash with (56.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Elevation Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference |
Elevation Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Elevation Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Elevation Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Elevation Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Elevation Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Elevation Oncology backward and forwards among themselves. Elevation Oncology's institutional investor refers to the entity that pools money to purchase Elevation Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sphera Funds Management Ltd. | 2024-09-30 | 1.1 M | State Street Corp | 2024-09-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 951.1 K | Orbimed Advisors, Llc | 2024-09-30 | 941.3 K | Millennium Management Llc | 2024-09-30 | 785.5 K | Ikarian Capital, Llc | 2024-09-30 | 690.1 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 543.3 K | Braidwell Lp | 2024-09-30 | 473.5 K | Ameriprise Financial Inc | 2024-09-30 | 440.5 K | Tang Capital Management Llc | 2024-09-30 | 4.8 M | Goldman Sachs Group Inc | 2024-09-30 | 4 M |
Follow Elevation Oncology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.6 M.Market Cap |
|
Project Elevation Oncology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.83) | (0.79) |
When accessing Elevation Oncology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Elevation Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Elevation Oncology's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Elevation Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elevation Oncology. Check Elevation Oncology's Beneish M Score to see the likelihood of Elevation Oncology's management manipulating its earnings.
Evaluate Elevation Oncology's management efficiency
Elevation Oncology has return on total asset (ROA) of (0.2546) % which means that it has lost $0.2546 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6367) %, meaning that it created substantial loss on money invested by shareholders. Elevation Oncology's management efficiency ratios could be used to measure how well Elevation Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. At this time, Elevation Oncology's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 1.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 3.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.61 | 1.37 | |
| Tangible Book Value Per Share | 1.61 | 1.37 | |
| Enterprise Value Over EBITDA | 0.02 | 0.02 | |
| Price Book Value Ratio | 0.33 | 0.35 | |
| Enterprise Value Multiple | 0.02 | 0.02 | |
| Price Fair Value | 0.33 | 0.35 | |
| Enterprise Value | -941 K | -894 K |
Elevation Oncology benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Return On Equity (0.64) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elevation Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elevation Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Elevation Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Elevation Oncology time-series forecasting models is one of many Elevation Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Elevation Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Elevation Oncology Earnings per Share Projection vs Actual
Elevation Oncology Corporate Management
| Joseph Ferra | Chief Officer | Profile | |
| Valerie MD | Chief Officer | Profile | |
| RPh PharmD | President, Founder | Profile | |
| Ryan Bloomer | Head CMC | Profile | |
| Biren Shah | Senior Development | Profile | |
| Brian Sullivan | VP Devel | Profile | |
| Candice Masse | Senior Relations | Profile |
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.